Biotech Startups

MultiplexDX develops a molecular diagnostics platform for cancer detection using proprietary technologies that combine histopathology, biomarker quantification, and gene expression analysis. The company serves research institutions and clinical laboratories internationally, with a focus on improving diagnostic accuracy in oncology.

1 investor

Multus designs cell culture media for the industrial bioeconomy, applying AI, robotics, and biological expertise to media formulation. It serves biomanufacturing companies producing cell-based therapies, food, and materials, aiming to reduce their time to market and improve supply chain and unit economics.

1 investor

Mumilk develops lab-grown human milk by recreating the function of mammary glands in vitro, aiming to produce nutrition containing bioactive molecules found in breast milk. The product is intended as an alternative for parents when breastfeeding is not an option.

1 investor

Mussel Polymers develops bio-inspired adhesive solutions based on mussel-derived chemistry for underwater, high-moisture, and specialized industrial applications including medical, military, and marine restoration. The company produces a patented polymer adhesive system that is nontoxic, environmentally friendly, and significantly stronger than conventional commercial alternatives.

1 investor

Mustang Bio in-licenses and develops next-generation therapies aimed at treating patients, operating in the biotechnology and therapeutics sector.

1 investor

MVM is a healthcare-focused investment firm that provides growth equity to companies in medical technology, pharmaceuticals, diagnostics, digital health, life science tools, and contract research and manufacturing. Operating from Boston and London since 1997, it partners with management teams to scale differentiated healthcare products across global markets.

1 investor

MVT in Silico develops computational platforms and simulation tools for drug discovery and biomedical research, enabling researchers to predict therapeutic effects and optimize drug development. The company serves pharmaceutical and biotechnology firms seeking to reduce late-stage development failures through model-informed drug development and in silico modeling.

1 investor

MVT Pharma develops ultrasound contrast agents and theranostics to advance imaging and treatment capabilities. The company focuses on drug discovery and development in medical imaging and oncology.

1 investor

My Gene Counsel offers a suite of digital genetic counseling and risk assessment tools, including its Living Lab Reports, that deliver continuously updated genomic insights to patients and providers. It serves biotech, hospitals and health systems, and pharmaceutical/research partners across the precision medicine care pathway.

1 investor

binx health develops FDA-cleared, CLIA-waived point-of-care diagnostic testing for chlamydia and gonorrhea in male and female patients, delivering central-lab-quality results in about thirty minutes so patients can test, get diagnosed, and receive treatment in one visit. The company operates in the diagnostics and sexual health space serving healthcare providers and their patients.

1 investor

Muse Bio produces a naturally derived, cell-free skincare ingredient from renewable biological resources and directs net proceeds to fund women's health research.

1 investor

MycoFoundry develops mycelium-based materials for architectural and interior applications, combining biotechnology and design. The company produces acoustic panels, furniture, and custom biofabricated materials for the built environment.

1 investor

Mycophyto develops biological solutions that leverage mycorrhizal fungi symbiosis with plants to enhance water uptake, nutrient access, and stress resistance, promoting sustainable and resilient agricultural production.

1 investor

CREATE Medicines develops in vivo CAR immunotherapy using proprietary mRNA-LNP technology to program T cells, NK cells, and myeloid cells directly within the body for cancer, autoimmunity, and fibrosis. The company's multi-immune platform enables off-the-shelf therapies with repeat dosing capability.

1 investor

MyForest Foods produces farm-grown mycelium as a new whole-food category, developing plant-based food products aimed at consumers seeking nutritious and environmentally friendly options. The company operates in the alternative protein and foodtech space.

1 investor

MyImmune develops AI that analyzes adaptive immune repertoire data to identify drug targets, predict patient responses to immunotherapies, and build biomarkers and companion diagnostics. It serves biotech, pharma, and CRO customers working in oncology, autoimmune, and infectious diseases.

1 investor

Mykito Sciences manufactures vegan, non-animal chitosan for medical, pharmaceutical, food, and industrial applications using advanced analytical facilities and GMP quality systems. The company achieves over 85% reduction in CO2 emissions compared to industry standards through its plant-based production methods.

1 investor

myNEO provides AI-powered software for drug discovery and development, specifically targeting antibody, bispecific, ADC, cell therapy, vaccine, and neoantigen-based immunotherapy programs. The company serves pharmaceutical and biotech organizations across target discovery, optimization, and data analysis stages.

1 investor

Myodenovo cultivates lab-grown meat, using scaffolds and bioreactors to produce premium cuts such as filet mignon without slaughtering animals. It targets meat consumers seeking high-quality, sustainable cultivated meat products.

1 investor

Cadre Bioscience partners with innovators to develop and bring new therapeutics to clinical application through drug development.

1 investor

Myoworks develops ancillary products for cultivated meat producers, including mycelium scaffolds, microcarriers, and cell lines that support lab cultivation of meat. The Indian biotech company aims to address scale and cost challenges in the cell-based meat industry.

1 investor

Myriad provides germline and tumor genomic testing across hereditary cancer, prenatal and reproductive health, prostate cancer, and pharmacogenomics for mental health medications. It supplies patients and healthcare providers with genetic screening results and AI-derived insights to inform diagnosis, risk assessment, and treatment decisions.

1 investor

Myrobalan Therapeutics is a pre-clinical biotech company developing small molecule therapies targeting microglia and oligodendrocytes to address neurodegeneration and demyelinating disorders. The company's precision medicines aim to promote remyelination and reduce neuroinflammation in conditions such as multiple sclerosis, Alzheimer's disease, and ALS.

1 investor

Newform Foods is a South African food technology company specializing in food and biotech research, operating the Newform Applied Biotech Centre at South Ormsby Estate in Lincolnshire.

1 investor